A multi-marker molecular signature approach for treatment-specific subgroup identification with survival outcomes.
Li L, Guennel T, Marshall S, Cheung LW.
Pharmacogenomics J. 2014 Mar 18. [Epub ahead of print]
MicroRNAs in personalized cancer therapy.
Sethi S, Ali S, Sethi S, Sarkar FH.
Clin Genet. 2014 Feb 14. [Epub ahead of print]
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
Pignatti F, Ehmann F, Hemmings R, et al.
Clin Cancer Res. 2014 Mar 15;20(6):1458-68.
FDA perspective on companion diagnostics: an evolving paradigm.
Mansfield EA.
Clin Cancer Res. 2014 Mar 15;20(6):1453-7.
Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion Diagnostics.
Senderowicz AM, Pfaff O.
Clin Cancer Res. 2014 Mar 15;20(6):1445-52.
Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.
Parkinson DR, McCormack RT, Keating SM, et al.
Clin Cancer Res. 2014 Mar 15;20(6):1428-44.
Gene expression profiling of Duchenne muscular dystrophy reveals characteristics along disease progression.
Tian LJ, Cao JH, Deng XQ, et al.
Genet Mol Res. 2014 Feb 28;13(1):1402-11.
Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing.
Huang Y, Zheng J, Hu JD, et al.
Genet Mol Res. 2014 Feb 19;13(1):945-53.
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.
Gustafson HL, Yao S, Goldman BH, Lee K, et al.
Am J Hematol. 2014 Mar 14. [Epub ahead of print]
Oncology reimbursement in the era of personalized medicine and big data.
Ward JC.
J Oncol Pract. 2014 Mar 1;10(2):83-6.
Implementation of a pharmacogenomics service in a community pharmacy.
Ferreri SP, Greco AJ, Michaels NM, et al.
J Am Pharm Assoc. 2014 Mar 1;54(2):172-80.
Using Pharmacogenetics in Real Time to Guide Therapy: The Warfarin Example.
Aminkeng F.
Clin Genet. 2014 Mar 13. [Epub ahead of print]
Associations of genetic risk score with obesity and related traits and the modifying effect of physical activity in a chinese han population.
Zhu J, Loos RJ, Lu L, et al.
PLoS One. 2014 Mar 13;9(3):e91442.
Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.
Zhu H, Deng FY, Mo XB, et al.
Pharmacogenomics. 2014 Mar;15(4):551-66.
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.
Brandl EJ, Tiwari AK, Chowdhury NI, et al.
Pharmacogenomics. 2014 Mar;15(4):423-31.
Implementation of genomic medicine in a health care delivery system: A value proposition?
Wade JE, Ledbetter DH, Williams MS, et al.
Am J Med Genet C Semin Med Genet. 2014 Mar 11. [Epub ahead of print]
PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics.
Hoffman JM, Haidar CE, Wilkinson MR, et al.
Am J Med Genet C Semin Med Genet. 2014 Mar 11. [Epub ahead of print]
Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the University of Chicago "1,200 Patients Project"
O'Donnell PH, Danahey K, Jacobs M, et al.
Am J Med Genet C Semin Med Genet. 2014 Mar 10. [Epub ahead of print]
Influence of SREBP-2 and SCAP Gene Polymorphisms on Lipid-Lowering Response to Atorvastatin in a Cohort of Chilean Subjects with Amerindian Background.
Lagos J1, Zambrano T, Rosales A, Salazar LA.
Mol Diagn Ther. 2014 Mar 11. [Epub ahead of print]
Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring.
Aomori T, Fujita Y, Obayashi K, et al.
J Clin Pharm Ther. 2014 Feb 25. [Epub ahead of print]
Utility of a Genomic-based, Personalized Medicine Test in Patients Presenting With Symptoms Suggesting Coronary Artery Disease.
Herman L, Froelich J, Kanelos D, et al.
J Am Board Fam Med. 2014 Mar-Apr;27(2):258-67.